Haemocomplettan P (Human Fibrinogen)

Haemocomplettan P is a lyophilized powder for solution for injection that contains the active ingredient human fibrinogen. It is supplied as a fibrinogen concentrate without a specified strength, intended for intravenous administration. The product is marketed in the European Union and is available only by prescription. Haemocomplettan P provides exogenous fibrinogen to support plasma fibrinogen levels in patients with bleeding disorders. It is used under supervision to correct hypofibrinogenemia in clinical settings.

Haemocomplettan P is indicated for the replacement of fibrinogen in patients with low plasma fibrinogen levels.

- Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) requiring fibrinogen supplementation. - Acquired hypofibrinogenemia associated with massive hemorrhage, trauma, or surgery. - Bleeding episodes in patients with disseminated intravascular coagulation where fibrinogen is depleted. - Peri‑operative management of patients with anticipated fibrinogen loss during cardiac or liver transplantation. - Supportive therapy for obstetric hemorrhage when fibrinogen levels are critically low.

Adverse reactions reported with Haemocomplettan P are generally related to the infusion process or to the protein nature of the product.

Common: - Mild fever or chills occurring during or shortly after infusion, typically self‑limiting. - Transient headache or dizziness that resolves without intervention. - Nausea, abdominal discomfort, or mild vomiting during the infusion period.

Serious: - Allergic reactions ranging from urticaria to anaphylaxis, requiring immediate medical attention. - Thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, or arterial thrombosis. - Volume overload leading to pulmonary edema, especially in patients with pre‑existing cardiac or renal disease.

When prescribing Haemocomplettan P, clinicians should consider several precautionary measures to ensure safe use.

- Verify baseline plasma fibrinogen level and monitor after administration. - Use caution in patients with a history of thromboembolic disease. - Assess cardiac and renal function before infusion to avoid volume overload. - Avoid rapid infusion rates; follow recommended administration guidelines. - Discontinue or adjust therapy if signs of allergic reaction develop. - Consider the risk of transmission of infectious agents despite viral inactivation steps.

Haemocomplettan P may interact with other agents that affect coagulation or fluid balance, requiring attention to concurrent therapy.

Avoid: - Concomitant use of pro‑coagulant agents (e.g., activated factor VII) that could increase thrombosis risk. - Simultaneous administration of large volumes of other plasma‑derived products without monitoring fibrinogen levels.

Use with caution: - Antifibrinolytic drugs (e.g., tranexamic acid) – monitor for excessive clot formation. - Heparin or other anticoagulants – adjust dosing based on coagulation tests. - Diuretics or fluid‑restrictive regimens – watch for signs of volume overload. - Immunosuppressive therapy – observe for potential altered immune response.